Crossref
journal-article
Elsevier BV
Current Opinion in Chemical Biology (78)
References
43
Referenced
73
10.1016/0092-8674(91)90499-O/ Cell / Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice by Soriano (1991)10.1016/S0065-230X(08)60774-5/ Adv Cancer Res / c-Src, receptor tyrosine kinases, and human cancer by Biscardi (1999)10.1002/(SICI)1097-0282(1998)47:3<243::AID-BIP4>3.0.CO;2-P/ Biopolymers / Src homology-2 domains: structure, mechanisms, and discovery by Sawyer (1998)10.2174/0929867003374390/ Curr Med Chem / Recent advances in the design and synthesis of SH2 inhibitors of Src, Grb2, and ZAP-70 by Vu (2000)10.1007/3-540-45035-1_2/ Top Curr Chem / Peptidomimetic SH2 domain antagonists for targeting signal transduction by Müller (2000)10.2174/1381612003401532/ Curr Pharmaceut Design / Progress in the development of inhibitors of SH2 domains by Cody (2000){'key': '10.1016/S1367-5931(00)00222-2_BIB7', 'first-page': '549', 'article-title': 'Signal transduction drug discovery: targets, mechanisms and structure-based design', 'volume': '3', 'author': 'Dalgarno', 'year': '2000', 'journal-title': 'Curr Opin Drug Disc Dev'}/ Curr Opin Drug Disc Dev / Signal transduction drug discovery: targets, mechanisms and structure-based design by Dalgarno (2000)10.1016/0092-8674(93)90404-E/ Cell / SH2 domains recognize specific phosphopeptide sequences by Songyang (1993)10.1016/S0960-894X(99)00388-1/ Bioorg Med Chem Lett / Structure-based design and synthesis of a novel class of Src SH2 inhibitors by Buchanan (1999)10.1016/S0960-894X(99)00389-3/ Bioorg Med Chem Lett / Structure-activity relationships of a novel class of Src SH2 inhibitors by Buchanan (1999)10.1021/ja971794t/ J Am Chem Soc / Structure-based design of a novel series of nonpeptide ligands that bind to the pp60src SH2 domain by Lunney (1997)10.1021/cc990074a/ Combinatorial Chem / Structure-based design and solid-phase parallel synthesis of phosphorylated nonpeptides to explore hydrophobic binding at the Src SH2 domain by Metcalf (2000)10.1021/jm0003337/ J Med Chem / Structure-based design of novel bicyclic nonpeptide inhibitors for the Src SH2 domain by Shakespeare (2000)10.1021/jo00250a043/ J Org Chem / Synthesis of new amino acids mimicking sulfated and phosphorylated tyrosine residues by Marseigne (1988)10.1021/jo00058a009/ J Org Chem / Preparation of fluoro- and hydroxy-4-phosphonomethyl-d,l-phenylalanine suitably protected for solid-phase synthesis of peptides containing hydrolytically stable analogues of O-phosotyrosine by Burke (1993)10.1016/S0065-7743(08)60937-9/ Annu Rep Med Chem / SH2 and SH3 domains: choreographers of multiple signaling pathways by Botfield (1995)10.1021/bi970019n/ Biochemistry / Peptide ligands of pp60c-src SH2 domains: a thermodynamic and structural study by Charifson (1997)10.1016/S0960-894X(98)00195-4/ Bioorg Med Chem Lett / The formation of a covalent complex between a dipeptide ligand and the Src SH2 domain by Alligwood (1998)10.1016/S0960-894X(99)00545-4/ Bioorg Med Chem Lett / An efficient synthesis of a 4′-phosphonodifluoromethyl-3′-formyl-phenylalanine containing Src SH2 ligand by Shakespeare (1999)10.1016/S1074-5521(00)00090-9/ Chem Biol / A Src SH2 selective binding compound inhibits osteoclast-mediated resorption by Violette (2000)10.1021/jm0002681/ J Med Chem / X-ray structure of citrate bound to Src SH2 leads to a high-affinity, bone-targeted Src SH2 inhibitor by Bohacek (2001)10.1016/0960-894X(96)00165-5/ Bioorg Med Chem Lett / Bone targeted drugs 2. synthesis of estrogens with hydroxyapatite affinity by Wilson (1996)10.1016/S0968-0896(99)00045-0/ Bioorg Med Chem / Prostaglandin E2-bisphosphonate conjugates: potential agents for treatment of osteoporosis by Gil (1999)10.1016/S8756-3282(00)00427-0/ Bone / Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption by Violette (2001)10.1073/pnas.97.17.9373/ Proc Natl Acad Sci USA / Structure-based design of a novel, osteoclast-selective, nonpeptide Src SH2 inhibitor with in vivo anti-resorptive activity by Shakespeare (2000)10.1016/0092-8674(92)90167-B/ Cell / The SH2 and SH3 domain-containing protein Grb2 links receptor tyrosine kinases to Ras signalling by Lowenstein (1992)10.1016/1056-8719(95)00082-7/ J Pharmacol Toxicol Methods / SH2 and SH3 domains: potential targets for anti-cancer drug design by Smithgall (1995)10.2174/1381612003398546/ Curr Pharmaceut Design / Structure-based design of compounds inhibiting Grb2-SH2 mediated protein-protein interactions in signal transduction pathways by Fretz (2000)10.1016/0959-437X(94)90087-6/ Curr Opin Genet Dev / SH2/SH3 signaling proteins by Schlessinger (1994)-
Lewis TS, Shapiro PS, Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res 1998:7449.
(
10.1016/S0065-230X(08)60765-4) 10.1021/jm970856n/ J Med Chem / Potent antagonists of the SH2 domain of Grb2: optimization of the X+1 osition of 3-amino-Z-Tyr(PO3H2)-X+1-Asn-NH2 by Garcı́a-Echeverrı́a (1998)10.1021/jm9702185/ J Med Chem / Discovery of 3-aminobenzyloxycarbonyl as an N-terminal group conferring high affinity to the minimal phosphopeptide sequence recognized by the Grb2-SH2 domian by Furet (1997)10.1021/jm980159a/ J Med Chem / Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain by Furet (1998)10.1016/S0960-894X(98)00701-X/ Bioorg Med Chem Lett / Highly potent inhibitors of the Grb2-SH2 domain by Schoepfer (1999){'key': '10.1016/S1367-5931(00)00222-2_BIB35', 'first-page': '235', 'article-title': 'Selective Grb2 inhibitors as anti-RAS therapy', 'volume': '83', 'author': 'Gay', 'year': '1999', 'journal-title': 'Cell'}/ Cell / Selective Grb2 inhibitors as anti-RAS therapy by Gay (1999)10.1074/jbc.274.33.23311/ J Biol Chem / Effect of potent and selective inhibitors of the Grb2 SH2 domain on cell motility by Gay (1999)10.2174/138161280303221007124221/ Curr Pharmaceut Design / Phosphotyrosyl-based motifs in the structure-based design of protein-tyrosine kinase dependent signal transduction inhibitors by Burke (1997)10.1016/S0960-894X(98)00740-9/ Bioorg Med Chem Lett / Monocarboxylic-based phosphotyrosyl mimetics in the design of Grb2 SH2 domain inhibitors by Burke (1999)10.1016/S0040-4020(99)00076-9/ Tetrahedron / Synthesis of Fmoc-protected 4-carboxydifluoromethyl-L-phenylalanine: a phosphotyrosyl mimetic of potential use for signal transduction studies by Yao (1999)10.1021/jm980388x/ J Med Chem / Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands by Yao (1999)10.1021/jm9904248/ J Med Chem / Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-malonyl)phenylalanine as a potent phosphotyrosyl mimetic by Gao (2000)- Lunney EA, Para KS, Plummer MS, Prasad JVNV, Saltiel AR, Sawyer TK, Shahripour A: Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins. 1997, WO patent 97/12903.
- Holt DA, Veber DF, Yamashita DS: Method of antagonizing the human Src SH2 domain for treating bone resorption diseases. 1998, WO patent 98/40093.
@article{Shakespeare_2001, title={SH2 domain inhibition: a problem solved?}, volume={5}, ISSN={1367-5931}, url={http://dx.doi.org/10.1016/s1367-5931(00)00222-2}, DOI={10.1016/s1367-5931(00)00222-2}, number={4}, journal={Current Opinion in Chemical Biology}, publisher={Elsevier BV}, author={Shakespeare, William C}, year={2001}, month=aug, pages={409–415} }